News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
724,699 Results
Type
Article (42838)
Company Profile (297)
Press Release (681563)
Multimedia
Podcasts (90)
Webinars (15)
Section
Business (210576)
Career Advice (2095)
Deals (36671)
Drug Delivery (107)
Drug Development (83158)
Employer Resources (175)
FDA (16647)
Job Trends (15440)
News (356408)
Policy (33996)
Tag
Academia (2600)
Accelerated approval (9)
Adcomms (23)
Allergies (101)
Alliances (51577)
ALS (112)
Alzheimer's disease (1461)
Antibody-drug conjugate (ADC) (161)
Approvals (16645)
Artificial intelligence (329)
Autoimmune disease (30)
Automation (19)
Bankruptcy (372)
Best Places to Work (11770)
BIOSECURE Act (20)
Biosimilars (128)
Biotechnology (188)
Bladder cancer (93)
Brain cancer (37)
Breast cancer (369)
Cancer (2911)
Cardiovascular disease (223)
Career advice (1758)
Career pathing (31)
CAR-T (188)
CDC (32)
Cell therapy (508)
Cervical cancer (22)
Clinical research (68416)
Collaboration (1044)
Company closure (3)
Compensation (695)
Complete response letters (28)
COVID-19 (2697)
CRISPR (62)
C-suite (333)
Cystic fibrosis (116)
Data (3014)
Decentralized trials (2)
Denatured (30)
Depression (63)
Diabetes (350)
Diagnostics (6509)
Digital health (23)
Diversity (9)
Diversity, equity & inclusion (45)
Drug discovery (143)
Drug pricing (135)
Drug shortages (31)
Duchenne muscular dystrophy (125)
Earnings (89161)
Editorial (42)
Employer branding (21)
Employer resources (151)
Events (116640)
Executive appointments (866)
FDA (18321)
Fibrodysplasia Ossificans Progressiva (2)
Friedreich's ataxia (4)
Frontotemporal dementia (9)
Funding (943)
Gene editing (136)
Generative AI (24)
Gene therapy (390)
GLP-1 (824)
Government (4629)
Grass and pollen (5)
Guidances (181)
Healthcare (19024)
HIV (40)
Huntington's disease (31)
IgA nephropathy (41)
Immunology and inflammation (157)
Immuno-oncology (9)
Indications (40)
Infectious disease (2870)
Inflammatory bowel disease (152)
Inflation Reduction Act (10)
Influenza (62)
Intellectual property (121)
Interviews (323)
IPO (16869)
IRA (51)
Job creations (4064)
Job search strategy (1494)
Kidney cancer (13)
Labor market (52)
Layoffs (518)
Leadership (20)
Legal (8401)
Liver cancer (80)
Longevity (12)
Lung cancer (405)
Lymphoma (210)
Machine learning (11)
Management (59)
Manufacturing (405)
MASH (92)
Medical device (13548)
Medtech (13553)
Mergers & acquisitions (20518)
Metabolic disorders (872)
Multiple sclerosis (97)
NASH (17)
Neurodegenerative disease (118)
Neuropsychiatric disorders (34)
Neuroscience (2159)
NextGen: Class of 2025 (6642)
Non-profit (4536)
Now hiring (47)
Obesity (443)
Opinion (242)
Ovarian cancer (102)
Pain (118)
Pancreatic cancer (121)
Parkinson's disease (188)
Partnered (22)
Patents (303)
Patient recruitment (167)
Peanut (53)
People (59679)
Pharmaceutical (91)
Pharmacy benefit managers (23)
Phase I (21223)
Phase II (30106)
Phase III (22543)
Pipeline (1650)
Policy (214)
Postmarket research (2654)
Preclinical (9057)
Press Release (68)
Prostate cancer (141)
Psychedelics (37)
Radiopharmaceuticals (259)
Rare diseases (479)
Real estate (6268)
Recruiting (68)
Regulatory (23499)
Reports (50)
Research institute (2375)
Resumes & cover letters (359)
Rett syndrome (9)
RNA editing (9)
RSV (49)
Schizophrenia (94)
Series A (161)
Series B (110)
Service/supplier (12)
Sickle cell disease (63)
Special edition (19)
Spinal muscular atrophy (151)
Sponsored (33)
Startups (3739)
State (2)
Stomach cancer (15)
Supply chain (77)
Tariffs (63)
The Weekly (58)
Vaccines (801)
Venture capital (54)
Weight loss (275)
Women's health (47)
Worklife (16)
Date
Today (50)
Last 7 days (370)
Last 30 days (1898)
Last 365 days (31703)
2025 (17038)
2024 (35771)
2023 (40630)
2022 (51797)
2021 (56329)
2020 (54791)
2019 (47397)
2018 (35770)
2017 (33137)
2016 (32662)
2015 (38615)
2014 (32516)
2013 (27630)
2012 (29729)
2011 (30487)
2010 (28497)
Location
Africa (783)
Alabama (61)
Alaska (7)
Arizona (250)
Arkansas (14)
Asia (41110)
Australia (6569)
California (7477)
Canada (2375)
China (694)
Colorado (323)
Connecticut (320)
Delaware (195)
Europe (87846)
Florida (1123)
Georgia (247)
Hawaii (1)
Idaho (59)
Illinois (653)
India (28)
Indiana (370)
Iowa (16)
Japan (234)
Kansas (108)
Kentucky (29)
Louisiana (14)
Maine (64)
Maryland (1030)
Massachusetts (5600)
Michigan (248)
Minnesota (453)
Mississippi (3)
Missouri (90)
Montana (28)
Nebraska (25)
Nevada (80)
New Hampshire (66)
New Jersey (2092)
New Mexico (29)
New York (2098)
North Carolina (1100)
North Dakota (8)
Northern California (3286)
Ohio (236)
Oklahoma (16)
Oregon (39)
Pennsylvania (1621)
Puerto Rico (17)
Rhode Island (36)
South America (1164)
South Carolina (35)
South Dakota (1)
Southern California (2795)
Tennessee (126)
Texas (1135)
United States (27822)
Utah (222)
Virginia (195)
Washington D.C. (72)
Washington State (640)
West Virginia (4)
Wisconsin (69)
724,699 Results for "ampio pharmaceuticals inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
BioMidwest
Ampio Pharmaceuticals Received Audit Opinion with Going Concern Explanation
Ampio Pharmaceuticals, Inc. announced that, as previously disclosed in its Annual Report on Form 10-K for the year ended December 31, 2023, which was filed on March 27, 2024 with the Securities and Exchange Commission, the audited financial statements contained an unqualified audit opinion from its independent registered public accounting firm that included an explanatory paragraph related to the Company’s ability to continue as a going concern.
April 3, 2024
·
1 min read
Ampio Provides Update on Results from Pre-IND Enabling Studies
Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) (the “Company” or “Ampio”) today announced the efficacy results from recently completed nonclinical pre-IND enabling studies with OA-201, Ampio’s only product development opportunity.
February 14, 2024
·
3 min read
Policy
Ampio Announces Voluntary Delisting and SEC Deregistration
Ampio Pharmaceuticals, Inc. announced that its Board of Directors determined to voluntarily delist its common stock from the NYSE American and deregister its common stock in order to terminate and suspend its reporting obligations under the Securities and Exchange Act of 1934, as amended.
March 25, 2024
·
4 min read
Ampio Selects Ascendia Pharmaceuticals, Inc. to Provide CDMO Services to Support Clinical Development of OA-201
Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) (the “Company) today announced that it has selected Ascendia Pharmaceuticals, Inc. (“Ascendia”) to provide services to support the clinical development of OA-201, a novel therapeutic for the treatment of symptomatic osteoarthritis pain.
October 5, 2023
·
5 min read
BioMidwest
Ampio Pharmaceuticals Announces Reverse Stock Split
Ampio Pharmaceuticals, Inc. announced that its Board of Directors has approved a 20-to-1 reverse stock split of the Company’s common stock.
August 31, 2023
·
4 min read
Ampio Pharmaceuticals to Present at the Emerging Growth Conference
Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) (the “Company”) a pre-revenue stage biopharmaceutical Company focused on development of a potential treatment for osteoarthritis as part of its OA.201 program, today announced that its CEO, Michael A. Martino will present in the Emerging Growth Conference on Thursday, October 5, 2023 at 3:25 pm ET.
September 26, 2023
·
3 min read
Policy
Investors who lost Money with shares of Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) should contact the Shareholders Foundation in connection with the Lawsuit against Ampio Pharmaceuticals, Inc.
The Shareholders Foundation, Inc. announces that a lawsuit is pending for certain investors in shares of Ampio Pharmaceuticals, Inc. (NYSE American: AMPE).
November 29, 2022
·
1 min read
BioMidwest
Ampio Pharmaceuticals Issues Letter to Stockholders - April 18, 2023
Ampio Pharmaceuticals, Inc. released the following letter to stockholders from its Chairman, Kevin Buchi and Chief Executive Officer, Mike Martino.
April 18, 2023
·
7 min read
Press Releases
UTILITY Therapeutics Announces Acquisition by Alembic Pharmaceuticals Inc.
July 3, 2025
·
7 min read
Press Releases
Rhythm Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
July 10, 2025
·
3 min read
1 of 72,470
Next
